source
- BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer studyThe companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.BioPharma Dive · 14d ago↗ source
- ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancerSac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first…BioSpace · 14d ago↗ source
- Roche warns Germany faces last chance to regain pharma investment confidenceRoche has said that recent German healthcare reforms threaten the country's attractiveness for pharmaceutical investment. The company paused its own German investment plans after the reforms were a…